Insulin secretion stimulation

“Insulin secretion stimulation” is not a discrete molecule or receptor but refers broadly to the physiological process by which pancreatic β-cells increase their release of insulin in response to various stimuli—primarily elevated blood glucose. This process involves multiple steps at the cellular level: When blood glucose rises after food intake, glucose enters β-cells via GLUT2 transporters. It is metabolized through glycolysis and mitochondrial oxidation, raising intracellular ATP levels. The increased ATP/ADP ratio closes ATP-sensitive potassium channels on the cell membrane, causing depolarization. This opens voltage-gated calcium channels; calcium influx triggers exocytosis of preformed insulin granules into circulation[4][5]. Additional amplifying signals come from amino acids, fatty acids, incretin hormones like GLP‑1 and GIP[3][4], neural input via acetylcholine[3], and paracrine/autocrine factors within islets[2]. Pharmacologically targeting this pathway underlies several antidiabetic therapies—most notably sulfonylureas acting on K_ATP channels and incretin-based therapies acting on GPCRs like the GLP‑1 receptor—but “insulin secretion stimulation” itself does not refer to a single actionable protein or gene product suitable for structured database entry as a canonical therapeutic target[4][5]. Therefore, “Insulin secretion stimulation” should not be considered a valid molecular target name; it describes an important physiological function regulated by many distinct proteins/receptors/channels within pancreatic β-cells rather than one specific entity amenable for drug targeting or biomarker development[4].

Other names

Insulin secretionStimulation of insulin releaseGlucose-stimulated insulin secretion (GSIS)Insulin secretagogue activity

Mechanisms relate to the molecular targets affected by drugs that stimulate insulin secretion. These include: – Closure of ATP-sensitive potassium channels leading to membrane depolarization and calcium influx [4][5] – Activation of GLP‑1 receptors increasing cAMP and enhancing exocytosis [3][5] – Modulation of intracellular signaling pathways such as PKA/PKC affecting vesicle fusion [6]